



NeoDynamics AB (publ)  
Q1 2023 Report

1 January – 31 March 2023

# Progress in the US

## First Quarter 2023

- Revenues amounted to SEK 318 (328) thousand, of which SEK 97 (92) thousand net sales, i.e., sales of finished products.
- Net loss amounted to SEK -23,233 (-15,852) thousand.
- Loss per share amounted to SEK -0.19 (-0.26).
- Cash and cash equivalents amounted to SEK 5,366 (20,067 at year-end) thousand.

## Significant events during the quarter

- NeoDynamics partners with Uniphar for US distribution and logistics. Uniphar is a global distribution and logistics giant and will help to ensure a successful US launch of NeoNavia®
- In February 2023 NeoDynamics' largest owner Gryningskust Holding AB offered the company a loan of SEK 14 million, with a fixed interest rate of 8%, which is within the market price range considering other similar financing. The loan maturity date is August 15th, 2023. The loan is intended to be converted into shares if the company issues new shares in the future, subject to shareholder approval.
- NeoDynamics announced that Jie Bao and Xiaojun Xu will step down from the Board of Directors as of 2023-02-14 based on a mutual agreement. They will instead focus on supporting the company and its plans for the Chinese market.
- NeoDynamics was granted Chinese patent for FlexiPulse needle design.

## Significant events after the end of the quarter

- NeoDynamics announces the delivery of CorePulse Needles to 23 Hospitals in the UK and Germany.
- NeoDynamics, Inc. announces U.S. availability of NeoNavia®, the first and only pulse biopsy technology, FDA-cleared in breast and axillary lymph node biopsies.
- The Extraordinary General Meeting resolved to adopt new Articles of Association where the limits for the share capital (§ 4) and the limits for the number of shares (§ 5) are changed, as regards the share capital to a ratio of SEK 12,000,000 to SEK 48,000,000 and as regards the number of shares to a ratio of 120,000,000 to 480,000,000 shares. The Extraordinary General Meeting also resolved that the board of directors, for the period until the end of the next annual general meeting, shall consist of four directors (previously six) and no deputy directors (unchanged) and to re-elect Ingrid Salén (chairman), Carina Bolin, Claes Pettersson and Matthew E. Colpoys, Jr.
- The final data set from NeoDynamics' PULSE study shows favorable safety and efficacy profile of NeoNavia for ultra-sound guided biopsies in the axillary lymph nodes. The data was presented at The SBI Breast Imaging Symposium, which took place on May 4-7, 2023.

## Progress in the US

One of our top priorities for this year is to ensure a successful launch of NeoNavia in the US. Operations are already in place through outsourced customer care and logistics. To drive sales, we have three very experienced sales representatives in the field who are establishing contact with top university hospitals and actively engaging with purchasing departments. We are satisfied with the progress so far.

NeoNavia was commercially launched at the American Society of Breast Surgeons (ASBrS) in Boston in the last week of April and at the SBI Breast Imaging Symposium in Maryland in the first week of May. This was a great opportunity for us to meet and interact with key opinion leaders and practitioners. ASBrS serves as the primary leadership organization for general surgeons who treat patients with breast disease and has grown to more than 3,000 members in the United States and 35 countries throughout the world. SBI is the leading network of breast radiologists and medical physicists in the U.S. Our PULSE study was accepted for electronic presentation at SBI which we are proud of as far from all abstracts are accepted.

### Advancement of our clinical program

Clinical tests typically start with a study to demonstrate the product's performance. This is the purpose of our PULSE study in Germany which included 138 patients diagnosed with breast cancer and in need of an axillary lymph node biopsy. The study has showed an impressive 93% success rate. The advantage of NeoNavia is that it is a minimally invasive option designed to provide controlled needle insertion, accurate lesion targeting, and high tissue yield from technically difficult lesions as well as difficult to access pathology.

Next step is to run a comparative study, where the product is compared with today's standard biopsy needle. Our COMPULSE study in the UK is a comparative study using the FlexiPulse needle to demonstrate product performance for ultrasound-guided biopsies of axillary lymph nodes in patients with breast cancer. Our product is tested on every second patient,



while every other patient is treated with a standard needle. The study was put on hold during the pandemic but has now been restarted. More than 400 patients will be recruited for this study, and the recruitment process has reached a key milestone of 100 patients.

### Supply of CorePulse needles in Europe and early feedback

In Europe, activity has picked up since the beginning of April, where the first production run of the new version of our CorePulse needle was shipped and delivered to hospitals in UK and Germany. The needles will now be used and evaluated in clinical practice.

Regarding feedback, firstly, we received very positive comments related to the yield. What we saw in our bench studies was replicated in clinical practice. Secondly, ease of use. Our product received positive comments regarding its simplicity to use; it's a one button press to initiate the procedure.

### Actions to secure financing

In the first quarter of 2023, we secured a loan from the Company's largest shareholder, Gryningskust Holding AB of SEK 14m, of which SEK 7m has been provided to kick-start the planned launch of NeoNavia® in the US. The loan is intended to be converted into shares if the Company issues new shares in the future. We are still in the process of exploring various options to raise long-term capital which includes, but is not limited to; debt financing, issuance of new shares, warrants and/or convertible instruments.

CEO Anna Eriksrud

# Financial overview

## Revenue and earnings

Revenues during the quarter amounted to SEK 318 (328) thousand, of which net sales were SEK 97 (92). Production has been restarted, which now includes feedback from our customers, which we have made in parallel to our US launch. The re-introduction of our CorePulse remains on-going, with centres in the UK and DACH region recently receiving their updated versions. We expect sales to start to materialize in the second half of the year, with the US commercial efforts solidifying.

Cost of goods were SEK 143 (60) thousand during the quarter, due to the phased roll out in the EU this year. Other external costs increased to SEK 12,004 (8,054) thousand, mainly reflecting higher costs for the establishment of NeoDynamics Inc., which is driven by the preparation of commercial activities in the US. We have also changed our financial reporting, to align better with a business with subsidiaries, consolidating our statements. In addition, as outlined in the CEO comments, we are exploring various options to raise long term capital, which has contributed to increased consultancy costs.

Personnel costs increased to SEK 6,652 (3,527) thousand during the quarter, an effect of several employees being onboarded in the US.

Operating loss amounted to SEK -23,115 (-15,844) thousand for the quarter whereas EBITDA, i.e., operating profit excluding depreciation, amounted to SEK -18,564 (-11,338) thousand for the quarter.

## Financial position

Cash and cash equivalents at the end of the period amounted to SEK 5,366 thousand (SEK 20,067 thousand at year-end).

Cash flow from operating activities before changes in working capital amounted to SEK -18,623, (-11,429) thousand and after changes in working capital to SEK -21,433 (-14,119) thousand. Receivables increased by SEK 664 thousand. The total cash flow amounted to SEK -14,713 (-14,147) thousand.

At period-end, the equity to assets ratio was 79 (89) percent and equity amounted to SEK 61,374 (81,516) thousand.

## The share

NeoDynamic's share was listed on Nasdaq First North Growth Market on May 2, 2022, with Redeye as Certified Adviser. The share's ticker is "NEOD" and the ISIN code is SE0011563410.

On June 30, 2022 the number of shares in NeoDynamics AB amounted to 120,501,184, up from 60,250,592, at year-end. A rights issue of 60,250,592 shares was completed during the second quarter of 2022, increasing the share capital by SEK 6,025,059 to SEK 12,050,119.

On March 31, 2023, the number of shares in the company was 120,501,184 and the last price paid in the period was SEK 0.492.

## Shareholders

On March 31, the company had a total of 4,247 shareholders, compared with 3,102 at year-end. The 10 largest shareholders at the end of the reporting period are listed in the table below.

Name	Shareholding	Ownership
Gryningskust Holding AB	16,844,360	14.00%
Fang, Huasheng	13,631,896	11.30%
NKY Sweden AB	4,922,544	4.10%
Avanza Pension	4,324,054	3.59%
SIX SIS AG, W8IMY	4,146,554	3.44%
Alandsbanken ABP	3,450,242	2.86%
Rentability Sweden AB	2,804,134	2.33%
Cardeon AB (PUBL)	2,803,234	2.33%
Futur Pension	2,444,306	2.03%
Nordnet Pensionsförsäkring AB	2,030,552	1.69%
Others	63,099,308	52.33%

### Financial calendar

Annual General Meeting	2023-05-23
Interim Report Jan-Jun	2023-08-17
Interim Report Jan-Sep	2023-11-16
Annual Accounts	2024-02-16

## Risks and uncertainties

A number of risk factors could have a negative impact on NeoDynamics AB's operations. It is therefore important to consider any relevant risks in addition to the company's growth opportunities. As of recent, we see an added uncertainty in our surrounding world, both as a result of Russia's invasion of Ukraine and through a financial instability with rising inflation and general macroeconomic uncertainty. The company now stands ready to commercialize its first main product. The board and company management are assessing alternatives to secure financing of the commercialization and the company's long-term capital requirements on an ongoing basis. For a detailed outline of the risks attributable to the company and its shares, please refer to the prospectus published by the Board in March 2022.

## Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and in accordance with the Swedish Accounting Standards Board's general advice BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3). For intangible assets, the activation model in the general council has been applied. The company's assets and liabilities are stated at cost and nominal value, unless otherwise stated.

## Review of the report

This interim report has not been reviewed by the company's auditor.

## Interim report submitted

The Board of Directors and the CEO hereby certify that this interim report provides a true and fair view of NeoDynamics' operations.

Lidingö on May 11, 2023

Anna Eriksrud  
CEO

Ingrid Salén  
Chairman of the Board

Carina Bolin  
Board member

Matthew E. Colpoys Jr  
Board member

Claes Pettersson  
Board member

NeoDynamics AB 559014-9117

### For further information, please contact

CEO Anna Eriksrud, phone +46 (0)708 444 966, e-mail [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

CFO Aaron Wong, phone +46 (0)79 010 1714, e-mail [aaron.wong@neodynamics.com](mailto:aaron.wong@neodynamics.com)

The company's Certified Adviser is Redeye AB.

## Income Statement

## Consolidated Accounts

Amount in SEK thousands	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec
<b>Revenue</b>			
Net sales	97	92	135
Work performed by the Company for its own use and capitalized	0	0	214
Other operating income	221	236	553
	<b>318</b>	<b>328</b>	<b>902</b>
<b>Operating expenses</b>			
Cost of goods	-143	-60	-947
Other external costs	-12,004	-8,054	-38,239
Personnel costs	-6,652	-3,527	-16,321
Depreciation/amortization of tangible and intangible assets	-4,591	-4,506	-18,144
Other operating expenses	-83	-25	-483
	<b>-23,473</b>	<b>-16,172</b>	<b>-74,134</b>
<b>OPERATING LOSS</b>	<b>-23,155</b>	<b>-15,844</b>	<b>-73,232</b>
<b>Financial items</b>			
Financial income	7	9	103
Financial costs	-85	-17	-3
<b>Net financial items</b>	<b>-78</b>	<b>-8</b>	<b>100</b>
<b>LOSS AFTER FINANCIAL ITEMS</b>	<b>-23,233</b>	<b>-15,852</b>	<b>-73,132</b>
Loss before tax	-23,233	-15,852	-73,132
Tax	0	0	-1,384
<b>NET LOSS</b>	<b>-23,233</b>	<b>-15,852</b>	<b>-74,516</b>
<b>EARNINGS PER SHARE BEFORE DILUTION, SEK</b>			
(no dilution)	<b>-0.19</b>	<b>-0.26</b>	<b>-0.73</b>
Number of shares at end of period	120,501,184	60,250,592	120,501,184
Average number of shares	120,501,184	60,250,592	102,627,636

## Balance sheet

## Consolidated Accounts

Amount in SEK thousands

	31 Mar 2023	31 Mar 2022	31 Dec 2022
<b>ASSETS</b>			
<b>Fixed Assets</b>			
Intangible assets	50,646	66,651	54,713
Tangible assets	1,735	1,589	1,575
Financial assets	138	123	138
	<b>52,519</b>	<b>68,363</b>	<b>56,426</b>
<b>Current Assets</b>			
Inventories	5,621	3,449	3,547
Accounts receivables	226	957	132
Other receivables	13,163	7,150	12,665
Prepaid expenses and accrued income	865	764	651
	<b>19,875</b>	<b>12,320</b>	<b>16,995</b>
<b>Cash and cash equivalents</b>	<b>5,366</b>	<b>10,785</b>	<b>20,067</b>
<b>TOTAL ASSETS</b>	<b>77,760</b>	<b>91,468</b>	<b>93,488</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Restricted Equity</b>			
Share capital	12,050	6,025	12,050
Other contributed equity	303,060	248,088	303,060
Other equity incl. profit/loss for the year	-253,736	-172,597	-230,539
<b>TOTAL EQUITY</b>	<b>61,374</b>	<b>81,516</b>	<b>84,571</b>
<b>Provisions</b>			
Provisions for guarantee	500	240	500
<b>Long-term liabilities</b>			
Other long-term liabilities	0	665	0
<b>Current liabilities</b>			
Accounts payable	1,141	3,858	1,742
Current tax liability	1,467	0	1,448
Other liabilities	7,579	443	162
Accrued expenses	5,699	4,746	5,065
	<b>15,886</b>	<b>9,047</b>	<b>8,417</b>
<b>TOTAL LIABILITIES AND PROVISIONS</b>	<b>16,386</b>	<b>9,952</b>	<b>8,917</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>77,760</b>	<b>91,468</b>	<b>93,488</b>



## Cash Flow Statement

## Consolidated Accounts

Amount in SEK thousands	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec
<b>Operating activities</b>			
Operating profit/loss	-23,155	-15,844	-73,232
Adjustments for items not included in cash flow	4,531	4,415	19,211
Interest received	1	0	32
Interest paid	0	0	-3
<b>Cash provided by operating activities before changes in working capital</b>	<b>-18,623</b>	<b>-11,429</b>	<b>-53,992</b>
<i>Cash from changes in working capital</i>			
Increase (-) / decrease (+) in inventories	-2,499	-904	-1,593
Increase (-) / decrease (+) in account receivables	-91	60	602
Increase (-) / decrease (+) in other receivables	-664	-1,063	-6,072
Increase (+) / decrease (-) in account payables	-602	-1,000	-3,134
Increase (+) / decrease (-) in other operating liabilities	1,046	217	-112
<b>Cash provided by operating activities</b>	<b>-21,433</b>	<b>-14,119</b>	<b>-64,301</b>
<b>Investing activities</b>			
Investment in intangible assets	-280	0	-1,100
Investment in tangible assets	0	-256	-760
Investment in financial assets	0	0	-14
<b>Cash used in investing activities</b>	<b>-280</b>	<b>-256</b>	<b>-1,874</b>
<b>Financing activities</b>			
Rights issue	0	0	69,288
Costs for rights issue	0	0	-8,382
Issuance of share options	0	228	338
Received loan	7,000	0	0
<b>Cash used in financing activities</b>	<b>7,000</b>	<b>228</b>	<b>61,244</b>
<b>Net change in cash and cash equivalents</b>	<b>-14,713</b>	<b>-14,147</b>	<b>-4,931</b>
<b>Cash and cash equivalents, opening balance</b>	<b>20,067</b>	<b>24,960</b>	<b>24,960</b>
Foreign exchange differences in cash	12	-28	38
<b>Cash and cash equivalents, ending balance</b>	<b>5,366</b>	<b>10,785</b>	<b>20,067</b>

## Income Statement

Amount in SEK thousands	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec
<b>Revenue</b>			
Net sales	3,239	92	1,379
Work performed by the Company for its own use and capitalized	0	0	214
Other operating income	23	54	154
	<b>3,262</b>	<b>146</b>	<b>1,747</b>
<b>Operating expenses</b>			
Cost of goods	-1,207	-48	-895
Other external costs	-13,005	-10,612	-48,650
Personnel costs	-3,004	-2,090	-7,613
Depreciation/amortization of tangible and intangible assets	-4,591	-4,506	-18,144
Other operating expenses	-63	-65	-311
	<b>-21,870</b>	<b>-17,321</b>	<b>-75,613</b>
<b>OPERATING LOSS</b>	<b>-18,608</b>	<b>-17,175</b>	<b>-73,866</b>
<b>Financial items</b>			
Result from shares in group companies	0	0	-4,184
Financial income	7	0	93
Financial costs	-25	-17	-3
<b>Net financial items</b>	<b>-18</b>	<b>-17</b>	<b>-4,094</b>
<b>LOSS AFTER FINANCIAL ITEMS</b>	<b>-18,626</b>	<b>-17,192</b>	<b>-77,960</b>
<b>Loss before tax</b>	<b>-18,626</b>	<b>-17,192</b>	<b>-77,960</b>
Tax	0	0	0
<b>NET LOSS</b>	<b>-18,626</b>	<b>-17,192</b>	<b>-77,960</b>
<b>EARNINGS PER SHARE BEFORE DILUTION, SEK</b>			
(no dilution)	<b>-0.15</b>	<b>-0.29</b>	<b>-0.76</b>
Number of shares at end of period	120,501,184	60,250,592	120,501,184
Average number of shares	120,501,184	60,250,592	102,627,636

## Balance sheet

NeoDynamics AB

Amount in SEK thousands	31 Mar 2023	31 Mar 2022	31 Dec 2022
<b>ASSETS</b>			
<b>Fixed Assets</b>			
Intangible assets	50,646	66,651	54,713
Tangible assets	1,735	1,576	1,575
Financial assets	3,510	370	371
	<b>55,891</b>	<b>68,597</b>	<b>56,659</b>
<b>Current Assets</b>			
Inventories	4,415	3,449	3,406
Accounts receivables	226	737	132
Receivables from group companies	3,934	1,819	1,385
Other receivables	12,631	5,587	12,205
Prepaid expenses and accrued income	741	763	531
	<b>21,947</b>	<b>12,355</b>	<b>17,659</b>
Cash and cash equivalents	<b>2,322</b>	<b>8,301</b>	<b>16,534</b>
<b>TOTAL ASSETS</b>	<b>80,160</b>	<b>89,253</b>	<b>90,852</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Restricted Equity</b>			
Share capital	12,050	6,025	12,050
Fund for development expenditure	45,543	61,532	49,606
	<b>57,593</b>	<b>67,557</b>	<b>61,656</b>
<b>Non-restricted Equity</b>			
Share premium reserve	303,060	248,088	303,060
Retained earnings	-279,489	-218,184	-205,592
Profit/loss for the year	-18,626	-17,192	-77,960
	<b>4,945</b>	<b>12,712</b>	<b>19,508</b>
<b>TOTAL EQUITY</b>	<b>62,538</b>	<b>80,269</b>	<b>81,164</b>
<b>Provisions</b>			
Provisions for guarantee	500	240	500
<b>Long-term liabilities</b>			
Other long-term liabilities	0	665	0
<b>Current liabilities</b>			
Accounts payable	1,109	3,230	1,515
Liabilities to group companies	2,079	0	3,526
Other liabilities	7,397	103	29
Accrued expenses	6,537	4,746	4,118
	<b>17,122</b>	<b>8,079</b>	<b>9,188</b>
<b>TOTAL LIABILITIES AND PROVISIONS</b>	<b>17,622</b>	<b>8,984</b>	<b>9,688</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>80,160</b>	<b>89,253</b>	<b>90,852</b>

## Key Figures

## Consolidated Accounts

	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023
Net sales, SEK thousands	92	10	32	0	97
Operating loss, SEK thousands	-15,847	-17,487	-14,626	-25,459	-23,155
Operating margin %	neg	neg	neg	neg	neg
Balance sheet total, SEK thousands	91,468	135,217	117,997	93,488	77,760
Equity ratio %	89%	93%	94%	90%	79%
Cash, SEK thousands	10,785	52,782	39,966	20,067	5,366
Earnings/loss per share, SEK	-0.26	-0.16	-0.12	-0.22	-0.19
Equity per share, SEK	1.35	1.04	0.92	0.70	0.51

## Statements of change in equity in summary (Amount in SEK thousands)

Consolidated Accounts	Jan-Mar		Jan-Dec
	2023	2022	2022
Balance at the beginning of the period	84,571	97,476	97,476
Warrant premium	0	0	338
Reclass costs	0	0	0
Reclass warrant premium	0	0	327
New share issue	0	0	69,288
Costs for new share issue	0	-92	-8,382
Translation difference	36	-16	40
Profit(-loss) for the period	-23,233	-15,852	-74,516
<b>Balance at the end of the period</b>	<b>61,374</b>	<b>81,516</b>	<b>84,571</b>

## Definitions

Earnings/Loss per share	Earnings/loss for the period / average number of shares
Equity / assets ratio	Total equity / total assets
Equity per share	Equity at the end of the reporting period / average number of shares
Operating margin	Operating profit / net sales

## Warrant program – 2020/2023 and 2022/2025

The company has implemented two incentive programs aimed at senior executives in the company. In 2020, 1,021,900 warrants were issued with the right for holders to for each option subscribe for one (1) share with a subscription price of SEK 4.71 during the period August 1, 2023 – September 30, 2023.

In 2022, 2,640,000 warrants were issued with the right for holders to for each option subscribe for one (1) share with a subscription price of SEK 1.74 during the period February 17, 2025 – May 17, 2025.

The Board's ambition is to propose the issuance of warrants or equivalent up to a maximum total dilution of 5%.

There are no dilution effects during the period. The warrant terms are available on the company's website.

## NeoDynamics in brief

*NeoDynamics AB (publ) is a Swedish medical technology company dedicated to advancing the diagnosis and care of cancer. The company has an innovative biopsy system, NeoNavia®. The biopsy system is based on patented pulse technology, developed from research carried out at the Karolinska Institute in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for accurate diagnosis and individualized treatment. The launch of NeoNavia® has been initiated in the UK, Germany, Sweden and the U.S.*

### A growing breast biopsy market

At least 6 million breast biopsies are performed every year in order to detect suspected cancer. Every year, about 2.1 million women are diagnosed with breast cancer, a number that increases by 5 percent annually. The market for breast cancer diagnostics is growing and was estimated in 2025 to reach 830 million US dollars. The proportion of non-surgical biopsies is increasing at the expense of the surgical ones. Extended screening programs and new screening techniques enable more and more tumors to be detected earlier. New therapies are increasing the need for biopsies to confirm diagnoses but also to follow up on treatment results.

### NeoNavia® – a unique biopsy system

NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by pulses, enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for accurate diagnosis and individualized treatment. The product has CE approval since 2016 and received FDA clearance in 2022

### New innovative technology

The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic driver that generates pulses is placed in a handheld instrument. Powered by the base unit, the driver accelerates the needle with great control even

over a short distance, enabling its distinct stepwise insertion without risking to destroy surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations as well as in dense tissue.

### Intellectual Property

The technology is protected in Europe's larger countries as well as in China and the USA. Patents for technology in the proprietary needle have been approved in Europe, the USA and China. The company's various patents run until 2034 and additional patent applications have been filed.

### Good results in clinical studies

The PULSE study (ClinicalTrials.gov ID: NCT03975855) shows that the system performs well when used in axillary lymph nodes. The patented pulse technology was considered to stabilize the target organ lymph node and improve needle control during insertion, and it was possible to obtain multiple samples with a single needle insertion.

### Tomorrow's breast cancer biopsy

NeoDynamics' vision is that our pulse technology will become the new standard for all ultrasound-guided breast cancer biopsies, and that precision and reliability will be improved, thereby helping to save lives and improve the quality of life of all women with breast cancer.

**“The NeoNavia® biopsy system can safely increase the precision of ultrasound-guided, technically difficult biopsies such as in the axillary lymph nodes.”**

Ref 1, Markets and Markets, September 2020 <https://www.marketsandmarkets.com/Market-Reports/biopsy-devices-breast-biopsy-market-189011805.html> Schässburger K, Paepke S. Po86. Novel pulse biopsy platform incorporating adaptive open-tip sampling needle increases sampling yield and needle control. *European Journal of Surgical Oncology*. 2021;47(5). doi:10.1016/j.ejso.2021.03.090.